Aerie Pharmaceuticals — Investor Presentation (October 2018)
26 slides from Aerie Pharmaceuticals's investor presentation, Oct 2, 2018
Slide 1: Company Overview Investor Presentation
Exhibit 99.1 Company Overview Investor Presentation October 2018
Slide 2: Important Information
Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified in their entirety
Slide 3: Aerie Overview
Aerie Overview Aerie IOP–Reducing Products (IP 2030+) • Rhopressa® (netarsudil ophthalmic solution) 0.02% • Successfully launched in U.S. April 30, 2018 • Roclatan™ (netarsudil / latanoprost ophthalmic solution) 0.02% / 0.005% • U.S. NDA accepted, PDUFA set for March 14, 2019 • Globalization Plan Un
Slide 4: Rhopressa: Market Perspective
Rhopressa ®: Market Perspective Lumigan 8% CAI 10% 2017 U.S. Glaucoma Market Travatan 7% AA 10% - ~$3B Market, 37M TRx, 61M bottles Fixed Latanoprost 37% - Half of volume first-line (PGAs) Combo 15% - Half of volume 2-3X/Day Adjuncts BB 13% Rhopressa®: HCP’s Positioning as Concomitant Therapy - New
Slide 5: Rhopressa Formulary Coverage Increasing
Rhopressa ® Formulary Coverage Increasing As of 10/01/18: ~85% of Commercial Lives Covered ~40% Medicare Part D Lives Covered Preferred Tier Non-preferred Tier 45% 55% 40% 40% 25% 12% 9/01/18 10/01/18 9/01/18 10/01/18 ------------Commercial------------- -----------Medicare Part D--------- For Invest
Slide 6: Rhopressa U.S. Launch Update
Rhopressa ® U.S. Launch Update Weekly IQVIA Total Rx’s and Extended Units: Week 24: 9/21/18 Week Ending 9/30/18: Wholesaler Shipments to Pharmacies = 5,876 *Holiday Weeks **Actual bottles dispensed exceed TRx’s due to extended supply plans (e.g., 90 days’ supply) Rhopressa® has not been approved by
Slide 7: Early Rhopressa Feedback
Early Rhopressa ® Feedback Physician Examples: End-stage glaucoma patient at brink of needing surgery. Patient on maximal medical therapy (PGA/Combo/CAI) with IOP of 18 mmHg. Added Rhopressa® and IOP dropped to 13 mmHg, avoiding surgery. Patient on maximal drug therapy and inadequately controlled at
Slide 8: Active Engagement at Key Conferences
Active Engagement at Key Conferences American Glaucoma Association of Society (AGS) Research in Vision March 2018 and Ophthalmology (ARVO) April 2018 European Glaucoma Society (EGS) Florence, May 2018 American Society of & Cataract and Refractive European Society of Surgeons (ASCRS) Cataract and Ref
Slide 9: Roclatan Combination Product Candidate
Roclatan TM Combination Product Candidate TM Roclatan (netarsudil / latanoprost ophthalmic solution) 0.02% / 0.005% Positioning as First Line Therapy: • Benefits of Rhopressa® while also targeting the secondary drain • Achieved statistical superiority to market-leading latanoprost - At each of nine
Slide 10: Roclatan Efficacy and Safety
RoclatanTM Efficacy and Safety Efficacy: • RoclatanTM demonstrated statistical superiority over its components (market- leading PGA latanoprost and Rhopressa®) in Mercury 1 and 2 Phase 3 trials, at all measured time points • Consistent incremental IOP-reduction over latanoprost and Rhopressa® in the
Slide 11: Roclatan Phase 3 Month 12 Responder Analysis
RoclatanTM Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patientswith IOP Reduced to 18 mmHg or Lower *p<0.05, **p<0.01, ***p<0.0001 ++Data on File Based on Mercury 1 Interim Analysis 2 For Investor Use 11
Slide 12: Roclatan Next Steps
Roclatan™ Next Steps • RoclatanTM NDA submission accepted, with March 14, 2019 PDUFA • Current U.S. sales force will be trained on RoclatanTM in advance of PDUFA • Commercial formulary access expected to be finalized post-approval • Medicare Part D formulary submission to payers expected in April 20
Slide 13: Expanding Aerie Franchise: Europe and Japan
Expanding Aerie Franchise: Europe and Japan • Europe (2017 Europe “Big 5” Glaucoma Market: 91M units per year, 1.5X U.S. units) • Expect to file MAA for Rhopressa® in 2018 • Current clinical plan expected to satisfy European regulatory requirements (including Rocket 4 for Rhopressa® and Mercury 3 fo
Slide 14: Europe Glaucoma Market
Europe Glaucoma Market: Aerie Expects to Commercialize on Its Own (if approved) “Big 5” Europe Glaucoma Market – 2017 $1.0B; 91M TRx*, Market Share in TRx Non-PGA Market (47%) PGA Market (53%) Others Bimatoprost 2 - 4 Times Daily CAI Once Daily 2% Travoprost 10% 13% 5% AA 4% Latanoprost 19% 17% Non-
Slide 15: Japan Glaucoma Market
Japan Glaucoma Market: Aerie Expects to Partner for Commercialization (if approved) Japan Glaucoma Market – 2017 $0.8B; 54M TRx*, Market Share in TRx Non-PGA Market (48%) PGA Market (52%) ROCK Others Unoprostone Inhibitors Bimatoprost 2 - 4 Times Daily 2% Once Daily 4% Travoprost (Unoprostone is bid
Slide 16: Advancing the Pipeline
Advancing the Pipeline • Rhopressa® Research Targets • 24-hour IOP reduction • Potential in normal tension glaucoma • Aqueous humor dynamics (trabecular outflow, episcleral venous pressure) • Pseudoexfoliative glaucoma • Corneal healing • Retina Program Opportunities: AR-1105 (dexamethasone steroid)
Slide 17: Retinal Eye Diseases – Aerie's Next Chapter
Retinal Eye Diseases – Aerie’s Next Chapter The retinal disease market is twice that of glaucoma with $4.9 billion in the U.S. and $9 billion worldwide per IQVIA Current treatments lose efficacy over time, some have very serious side effects and there are limited surgical options The majority of cur
Slide 18: 2017 U.S. Retinal Disease Market
2017 U.S. Retinal Disease Market 2017 Sales: $5.3B Unit Sales: 6.8M steroids, steroids, others, others, 0.23 $0.15 $0.02 0.11 Lucentis, 0.86 Lucentis, $1.44 Eylea, 2.61 Eylea, $3.70 Avastin, $0.02 Avastin, 3.03 Sources: Mix of public information, IQVIA and estimates For Investor Use 18
Slide 19: AR-1105: Dexamethasone Implant
AR-1105: Dexamethasone Implant • Target indications • Macular edema due to diabetic retinopathy (DME) • Macular edema due to retinal vein occlusion (RVO) • Unmet need • First line anti-VEGF agents often not sufficient even with monthly intravitreal (IVT) injections • Current second-line steroid trea
Slide 20: AR-13503: A First-in-Class ROCK/PKC Inhibitor
AR-13503: A First-in-Class ROCK/PKC Inhibitor for the Treatment of Wet AMD and DME • Active metabolite of netarsudil • Potential to improve outcomes by targeting multiple disease processes • Monotherapy shows strong efficacy in preclinical models • Effective as adjunct to anti-VEGF therapy in precli
Slide 21: Preclinical AR-13503 Provides Efficacy Similar to Eylea
Preclinical AR-13503 Provides Efficacy Similar to Eylea® in a Proliferative Diabetic Retinopathy Model Oxygen-induced retinopathy (OIR) mouse model - PDR Vehicle 1.25 mg/kg AR-13503 1 mg/kg Eylea (n=14) (n=16) (n=14) Administration: Intraperitoneal QD Data on File For more information on Eylea® plea
Slide 22: AR-13503 Synergistic to Eylea in Mouse Model
AR-13503 Synergistic to Eylea® in Mouse Model of Proliferative Diabetic Retinopathy Oxygen-induced retinopathy (OIR) mouse model - PDR Neovascular Area (+SEM) *** 35% 30% * * : p<0.01 *** : p<0.0001 25% -40% 20% -60% 15% 10% 5% 0% Vehicle Eylea (sub- AR-13503 (sub- Combination n=12 optimal dose) opt
Slide 23: DSM Collaboration – Implant Delivery Technology
DSM Collaboration – Implant Delivery Technology • Bio-erodible implant technology • Aerie now has a worldwide exclusive license for all ophthalmic indications • Broad sustained release platform for treatment of Wet AMD and DME, as well as glaucoma • Promising results from ongoing feasibility study •
Slide 24: PRINT Technology for Ophthalmology
PRINT® Technology for Ophthalmology Micropatterned Mold formation Mold Filling Particle Array Template (e.g. drug/polymer) PRINT= Particle Replication In Non-wetting Templates Aerie has the rights to use this technology for ophthalmic applications Proprietary technology capable of creating precisely
Slide 25: Evaluating Aerie's 3,500+ Owned Molecules
Evaluating Aerie’s 3,500+ Owned Molecules • Commencing screening for additional indications beyond ophthalmology • ROCK inhibition should have potential in: • Pulmonary health, ROCK including pulmonary fibrosis and bronchial asthma • Dermatology indications • Cancer Aerie molecules inhibit both ROCK
Slide 26: Summary
Summary • Key Priorities • Rhopressa®: Successful launch execution • RoclatanTM : U.S. PDUFA set for March 14, 2019 • Globalization Strategy • Europe/Japan clinical path and commercialization strategy • Ireland Manufacturing Facility • Research Initiatives • Rhopressa® 24-hour IOP reduction, normal
Aerie Pharmaceuticals — Investor Presentation (October 2018) on 6ix